MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
TB-500 + BPC-157 Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
The TB-500 and BPC-157 stack is the same combination as the BPC-157 plus TB-500 protocol, pairing the N-terminal actin-binding fragment of thymosin beta-4 with Sikiric's pentadecapeptide Body Protection Compound, listed with TB-500 first to reflect supplier and protocol naming conventions. The mechanistic case for combining them rests on non-overlapping repair pathways: TB-500 sequesters monomeric G-actin to promote cytoskeletal remodeling, cell migration, VEGF upregulation, and bone marrow-derived endothelial progenitor recruitment to wound sites, while BPC-157 drives angiogenesis through VEGFR2 signaling and modulates nitric oxide, dopaminergic, and serotonergic tone in tissue repair models. Researchers and unsupervised users apply the stack to tendon, ligament, and muscle injury recovery, post-surgical wound healing, and gastrointestinal inflammation models. Source literature is summarized in PMID 17204577 (Goldstein thymosin beta-4 review) and PMID 30915550 (Sikiric BPC-157 review). No human randomized controlled trial has tested the combination directly.
Reconstitute: Add 2 mL bacteriostatic water → 2.5 mg/mL concentration.
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 0.0250 mg (25 mcg) on a U-100 insulin syringe.
Storage: Refrigerate lyophilized and reconstituted solutions; use within ~30 days after reconstitution.
Dosing cadence: TB-500 has a 2 to 3 day plasma half-life and is typically given twice weekly; BPC-157 is short in plasma but stable in gastric juice and is usually given once or twice daily, producing an asymmetric protocol.
Onset: Single-agent animal models show histologic and functional repair within 7 to 21 days. Anecdotal combined human reports describe symptom changes over 2 to 4 weeks but without controlled comparison.
Regulatory status: Neither component is approved by FDA, EMA, or other major regulators. Both are WADA-prohibited (TB-500 under S2; BPC-157 under S0). BPC-157 also restricted by FDA 503A category 2 listing for US compounding.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Interactive TB-500 + BPC-157 Syringe Calculator
Currently visualizing the 5 mg + 5 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 2mL water yields 2.50 mg/mL. To evaluate a 250mcg dose, pull to 10.0 units (10 syringe ticks).
U-100 Syringe Representation
10.0 Units (10 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–4 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Twice weekly |
| Weeks 5–12 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Once weekly |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
| Week | Daily Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
| Weeks 3–8 | 500 mcg (0.50 mg) | 20 units (0.20 mL) | Once daily |
| Weeks 9–12 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg + 5 mg vial.
TB-500 Vials (5 mg each):
- check8 weeks ≈ 3 vials
- check12 weeks ≈ 4 vials
- check16 weeks ≈ 5 vials
BPC-157 Vials (5 mg each):
- check8 weeks ≈ 5 vials
- check12 weeks ≈ 7 vials
- check16 weeks ≈ 8 vials
Insulin Syringes (U-100):
- check8 weeks: 68 syringes (TB-500: 12 + BPC-157: 56)
- check12 weeks: 100 syringes (TB-500: 16 + BPC-157: 84)
- check16 weeks: 132 syringes (TB-500: 20 + BPC-157: 112)
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- check8 weeks (8 total vials): 16 mL → 2 × 10 mL bottles
- check12 weeks (11 total vials): 22 mL → 3 × 10 mL bottles
- check16 weeks (13 total vials): 26 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- check8 weeks: ~160 swabs → recommend 2 × 100-count boxes
- check12 weeks: ~232 swabs → recommend 3 × 100-count boxes
- check16 weeks: ~304 swabs → recommend 4 × 100-count boxes
Mechanism of Action (MOA)
Designing a TB-500 and BPC-157 protocol is a question of matching dosing frequency to the pharmacokinetics and biological effect duration of each peptide. TB-500 (the synthetic active region of thymosin beta-4, residues 17-23 with sequence LKKTETQ) has a short plasma half-life of approximately 2 hours after subcutaneous injection, but its biological effects on actin polymerization, cell migration, angiogenesis, and inflammatory modulation are tissue-incorporated and persist for several days because the peptide is taken up into target cells and its downstream transcriptional and protein-level effects outlast peptide presence [4][5]. This pharmacokinetic-pharmacodynamic dissociation supports infrequent dosing: most published research protocols use TB-500 at 2 to 5 mg twice weekly during a 4 to 6 week loading phase, followed by maintenance at 2 mg once weekly for an additional 4 to 8 weeks. BPC-157 is unusually stable in serum and resistant to gastric hydrolysis compared with most peptides of similar length, but its mechanism (VEGFR2-mediated angiogenesis, ERK1/2-mediated fibroblast proliferation, growth hormone receptor upregulation) depends on continuous local signaling during the repair window. Research protocols therefore use small daily doses of BPC-157, typically 250 to 500 mcg/day subcutaneously, throughout the entire 4 to 12 week cycle [6][7][8]. The loading phase architecture pairs TB-500 at 2 to 5 mg subcutaneously twice weekly (typically Monday and Thursday or similar spacing) with BPC-157 at 250 to 500 mcg subcutaneously once daily, ideally split into morning and evening sub-doses for higher daily totals. The maintenance phase reduces TB-500 to 2 mg once weekly while continuing BPC-157 at the same daily dose. Some protocols include a taper phase in the final 1 to 2 weeks of the cycle: BPC-157 reduced to 200 mcg/day and TB-500 discontinued, allowing biological effects to consolidate before complete cessation. Cycle length varies by indication: acute soft tissue injury (acute Achilles tendinopathy, hamstring strain) typically runs 4 to 6 week cycles; chronic tendinopathy (chronic patellar or rotator cuff tendinopathy) may extend to 8 to 12 weeks; post-surgical orthopedic recovery (ACL reconstruction, rotator cuff repair) often runs 8 to 12 week cycles aligned with the surgical biology. Rest periods between cycles are commonly 4 to 8 weeks to avoid presumed receptor desensitization and to monitor whether benefits persist after discontinuation. Injection sites for TB-500 are typically the abdomen or thigh (systemic effects) while BPC-157 may be injected near the site of injury (local effects) or in the abdomen (systemic effects). Some protocols use intramuscular injection of BPC-157 directly into the muscle adjacent to a tendon or ligament injury based on preclinical evidence of local activity. The combination is banned in competitive sport by WADA under category S2.
Clinical Trial Efficacy Highlights
- starLoading-phase efficacy in animal tendon injury models has shown that combined twice-weekly TB-500 plus daily BPC-157 produces faster restoration of biomechanical strength, collagen organization, and tendon fibroblast migration compared with either peptide alone, supporting the use of distinct loading schedules for each component [4][6][9].
- starMaintenance-phase protocols using TB-500 at 2 mg once weekly plus BPC-157 at 250 to 500 mcg daily for 4 to 8 additional weeks after loading have been associated in observational reports with continued improvements in tendon stiffness on ultrasound and return-to-activity timelines, although controlled trial data are absent [3].
- starSikiric and colleagues' preclinical work supports continuous daily BPC-157 dosing throughout the healing window rather than intermittent dosing, because VEGFR2 and growth hormone receptor upregulation depend on sustained local signaling rather than peak exposure [6][8].
- starGoldstein and colleagues' work on thymosin beta-4 establishes that the biological effects of TB-500 outlast peptide presence by days because the peptide is incorporated into target tissues and triggers durable transcriptional programs, supporting infrequent dosing during loading [4][5].
- starChang and colleagues demonstrated in tendon fibroblasts that BPC-157 produces dose- and time-dependent upregulation of growth hormone receptor expression by approximately 3-fold; this provides a mechanistic anchor for the continuous-daily-dosing schedule of BPC-157 within combination protocols [8].
- starCycling and taper schedules (4 to 8 week active cycles separated by 4 to 8 week rest periods) reflect best-practice extrapolation from longer published preclinical timelines and represent the dominant convention in research-use peptide protocols, although no head-to-head comparison of cycling versus continuous dosing has been published [1][2].
- starTopical and oral BPC-157 formulations may be used adjunctively during the maintenance and taper phases of injection protocols, leveraging the unusual oral bioavailability of BPC-157 to sustain local gastrointestinal or systemic effects without daily injections [6].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningLoading-phase tolerability is typically the most challenging period; injection site reactions are most common during the first 1 to 2 weeks while injection technique is being refined, and rotating injection sites between abdomen, thigh, and gluteal regions helps minimize local discomfort.
- warningTransient fatigue, mild lethargy, and flu-like symptoms have been described anecdotally during the first 3 to 7 days of loading, possibly reflecting initial immune modulation; most users find these resolve spontaneously without dose adjustment.
- warningMaintenance-phase tolerability is usually excellent because weekly TB-500 spacing eliminates the cumulative injection burden of loading; BPC-157 daily dosing remains the principal source of injection site reactions during maintenance.
- warningTheoretical concerns about angiogenesis-related effects on occult malignancy apply throughout the protocol; both peptides drive vascular and progenitor-cell activity that could theoretically support tumor growth, although no direct clinical evidence has been demonstrated.
- warningWADA prohibition under category S2 applies to both peptides; competitive athletes face sanctions if either component is detected, and longer detection windows for TB-500 (because of tissue incorporation) make planning a clean window before competition difficult.
- warningCycling-related concerns include incomplete healing if cycles are truncated below preclinical timelines; conversely, extended continuous use without rest periods has not been characterized for safety.
- warningDrug-drug interactions during loading should be considered for athletes or research subjects also using anticoagulants, NSAIDs, or other angiogenesis-modulating agents; no formal pharmacokinetic interaction data exist.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical TB-500 and BPC-157 dosage?expand_more
Loading: TB-500 at 2 to 5 mg subcutaneously twice weekly plus BPC-157 at 250 to 500 mcg subcutaneously daily for 4 to 6 weeks. Maintenance: TB-500 at 2 mg weekly plus BPC-157 at 250 to 500 mcg daily for an additional 4 to 8 weeks. Taper: BPC-157 reduced to 200 mcg/day in final 1 to 2 weeks, TB-500 discontinued.
How is TB-500 and BPC-157 used in research protocols?expand_more
Cycles vary by indication: acute soft tissue injury 4 to 6 weeks; chronic tendinopathy 8 to 12 weeks; post-surgical orthopedic recovery 8 to 12 weeks aligned with surgical biology. Rest periods of 4 to 8 weeks between cycles are common to monitor durability of benefit and avoid presumed receptor desensitization.
Can TB-500 and BPC-157 be combined with other peptides?expand_more
The two-peptide stack is often expanded with KPV (anti-inflammatory) and GHK-Cu (tissue remodeling) for the four-peptide healing protocol. Growth hormone secretagogues such as ipamorelin and CJC-1295 are sometimes added for systemic anabolic support, scheduled separately from the healing injections.
What are the side effects of TB-500 and BPC-157?expand_more
Loading phase produces the most injection site reactions and occasional transient fatigue. Maintenance phase is usually well tolerated. Theoretical concerns about angiogenesis effects on occult malignancy apply throughout. The combination is banned by WADA, with TB-500 carrying a longer detection window because of tissue incorporation.
Is TB-500 and BPC-157 FDA approved?expand_more
No. Neither peptide is FDA approved for any indication, and the combination has no regulatory status. FDA placed BPC-157 in Category 2 of the 503A compounding list in late 2023, effectively restricting compounded pharmacy access in the United States. Use remains research-only.
Academic References & Study Citations
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. View Scientific Paper →
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Curr Sports Med Rep. 2025;24(8):278-289. View Scientific Paper →
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. View Scientific Paper →
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. View Scientific Paper →
Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. View Scientific Paper →
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. View Scientific Paper →
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. View Scientific Paper →
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. View Scientific Paper →
Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. View Scientific Paper →